1. Biobanking
Americas
The future for next generation drug discovery and personalised medicines
9th - 11th November 2010, Boston, USA BOOK NOW!
Key Speakers
Dr.MarcAllard,ResearchMicrobiologist,CenterforFoodSafetyandAppliedNutrition, FDA
Dr.AdelLaoui,Director,HealthcareTechnologiesAgingTherapeuticStrategicUnit,Sanofi-aventis
BrendaYanak,WestPointITSiteHeadandAccountManager,FranchiseBiology,siRNA,Imaging,andGeM, Merck
JeffMilton,BioinformaticsComputationalBiology,Genentech
Dr.JohnG.Baust,UNESCOChairProfessor,Director,InstituteofBiomedicalTechnology, State University of New York
ElaineW.Gunter,FounderandPresident,SpecimenSolutions,LLC, National Cancer Institute
Dr.HartmutJuhl,CEO,Indivumed
JamesEliason,Director, Stem Cell Commercialization Center
Dr.MichaelHehenberger,BusinessDevelopmentExecutive,LifeSciences, IBM Thomas J. Watson Research Center
KristenRosati,Partner,Coppersmith Schermer Brockelman
Dr.RichardJ.Maguire,DirectorofBusinessDevelopment–LIMS,Ocimum Biosolutions
Pre-conference Workshop, 9th November 2010
The role of best and evidence based practice in promoting quality sample and data
collection to support biomarker research and development
Led By: Lisa B Miranda, Vice President, Strategic Alliances and International Biobank Relations, Trans-Hit Biomarkers
Driving the Industry Forward | www.futurepharmaus.com
Organised By
Media Partners
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/biobankingamericas

2. Conference Introduction
Biobanking Americas
9th - 11th November 2010, Boston, USA
An estimated $1bn has been invested in the biobanking industry Media Partners:
within the last ten years. At least 179 biobanks with 345,000
donors exist in the US, most of which were established in the last PharmiWeb.com is the leading industry-sponsored portal for
10 years. (Source: Business Insights, March 2009) the pharmaceutical sector. Supported by most of the leading
pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news,
Dear Colleague, features, events listings and international jobs to industry professionals across
TIME Magazine highlighted biobanking as one of “10 Ideas Changing the World Right Europe and the US.
Now.” Biobanking is rapidly growing and thriving to change approaches to target- For further information please email: corporate@pharmiweb.com
finding, drug development and patient treatment. It is being viewed as a key driver for
next generation biomarker and drug discovery. BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
The substantial advancement of research on the human genome has led to the creation WORLD. It is based and located in Warsaw, Poland.
of biobanks, which has brought a paradigm shift in drug testing and development. Biotechnology World was founded in 2007 to provide the world’s biotech and
Recognizing the potential benefits from biobanks, pharma and biotech across the world pharma information and market to make it universally accessible and useful
are investing in infrastructure and biobank development. for scientific and business processes. Its first step to fulfilling that mission was
Biobanking Americas reflects the broad spectrum of strategic approaches in biosample building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of
management. Visiongain is proud to be hosting this important conference, which will information in different channels. BIOTECHNOLOGY EUROPE offers companies
bring together a panel of experts, comprising scientists, regulators, researchers who completed internet public relations, publication and marketing solutions. One
will provide you with practical knowledge and strategic advice on new models and of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and
theoretical frameworks of biobanking. In addition to this, the conference will enable Pharma Sector in Europe to global biotechnology, pharmaceutical and life science
participants to identify and overcome the ethical, legal and social challenges. activities.
For further information please visit www.biotechnology-europe.com
Reasons to register today:
• Learn how to develop the best practices to leverage biospecimen resources Future Pharmaceuticals has forged powerful relationships
Driving the Industry Forward | www.futurepharmaus.com
• Analyse major challenges for biorepository management and implementation with key industry leaders to provide a platform for successful
• Get the latest updates on the applications on genome sequencing brand recognition, and for senior decision-makers to have the means to procure
and plan implementation strategies based on the topics covered. Positioned
• Investigate the future of biobanks, regulation, ethics, investment and the humanization
of drug discovery in the Americas
to be an authoritative resource within top pharma companies as well as small,
specialty, and biotech, Future Pharmaceuticals magazine is geared to create a
• Determine how to implement virtual biorepository deep penetration into a highly targeted and responsive audience, bridging the gap
• Understand the importance of quality management in biobanking between the industries’ top issues and the solutions top-tier vendors can provide.
• Gain an insight into the bioprospecting of tissues, DNA, protein or genetic For further information please visit: www.futurepharmaus.com
information
• Enable confident decision making by benchmarking yourself against other leaders in
InPharm is the online platform for exclusive pharmaceutical
the field news, comment, contracts, services, jobs and events and is
home to InPharmjobs.com, Pharmafile and Pharmafocus.
I look forward to meeting you at the conference For further information please visit: www.In-Pharm.com
Best regards
Pharma Connections Worldwide® is the leading professional
business networking website focused in the Pharmaceutical,
Biotechnology and Life Sciences research industry. Our goal is to provide a
PranitaNangia conduit for delivery of premiere content coupled with the right clientele in order
to facilitate business development opportunities among industry professionals
HeadofConferences
responsible for making key decisions in a global marketplace.
For further information please visit: www.pharmaconnections.com
Who should attend?
VPs, Directors, Heads, Managers of:
• Biobank Sponsorship and exhibition opportunities:
• Tissue bank
• Biorepository/BioSample
This event offers a unique opportunity to meet and do business with some of the
• Molecular Diagnostics key players in the pharmaceutical and biotech industries. If you have a service or
• Clinical Genetics, Pathology
• Genomics product to promote, you can do so at this event by:
• Privacy/Protection/Security
• Scientific and Quality • Hosting a networking drinks reception
• Laboratory and Inventory
• RD • Taking an exhibition space at the conference
• Quality Control
• Strategic Outsourcing • Advertising in the delegate documentation pack
• Clinical Research
• Translational Medicine • Providing branded bags, pens, gifts, etc.
• Personalized Medicine
• Bioanalytical Chemistry If you would like more information on the range of sponsorship or exhibition
• Pharmacogenomics
• Proteomics possibilities for visiongain's Biobanking Americas Conference, please contact us:
• Business development
• Strategic alliances Ronald Magali, +44 (0)20 7549 9934
Others:
ronald.magali@visiongainglobal.com
Consultants Academics
Regulatory bodies
Researchers Christopher Clegg, +44 (0)20 7549 9943
Biorepository Vendors
christopher.clegg@visiongainglobal.com
Government Officials

3. Pre-Conference Interactive Workshop
Biobanking Americas
Tuesday 9th November 2010
The role of best and evidence based practice in promoting quality sample
and data collection to support biomarker research and development
Led by: Lisa B Miranda Timings: 09:30 - 10:00 Coffee Registration
Vice President, Strategic Alliances and 10:00 - 15:00 Workshop
International Biobank Relations
Timing includes lunch and refreshment breaks
Trans-Hit Biomarkers
About the workshop: About your workshop leader:
Many consider biobanks to be the crucial cornerstone of
biomedical research through their provision of expertise and Lisa B Miranda
procurement of high quality samples and well annotated
data to foster research. One’s ability to develop high utility, With over 20 years of experience, Ms. Miranda
impactful, yet quality biobanking collections lies in the has a vast range of expertise in all aspects of
biospecimen resource’s success in implementing current best Biospecimen Resource Research Management and
practice as well as the foresight to incorporate evidence Development. After 14 years in research at the University
based practice into daily operations. The role of the of Pennsylvania, Ms. Miranda attained international
biobanker is now expanding to include proactive pipeline prominence as Technical Director of the Tumor Tissue and
planning which incorporates these considerations to ensure Biospecimen Bank (TTAB) Core Facility. She served as the
successful “proof of concept” in translational research prime architect of the centralized biospecimen resource
efforts such as biomarker research and development. and led TTAB’s collaborative efforts in development of the
NCI’s CaTissue Suite inventory management system and a
This interactive workshop will include discussion of: National Mesothelioma Virtual Bank with the University of
• An overview of related best and evidence based practice Pittsburgh and the CDC. In 2006, she was recognized for her
issues development of a Sustainable Cost Recovery Model which
• The role and current implications of best and evidence was acknowledged as the gold standard by the United
based practice in the biobanking workspace that relate to States National Cancer Institute’s Office of Biorepositories
pipeline planning and Biospecimen Research (NCI OBBR). Since then she has
• Strategies for how to navigate the RD pathway and continued to establish and develop best practices for the
build a biomarker discovery pipeline for your biobank that biobanking community through her role as a NIH Contractor
integrates evidence based practice and Consultant for NCI OBBR and the Biospecimen Research
for Molecular Medicine Offices, as well as current work on
cost recovery for the ISBER Best Practices (2010 version).
In addition to collaborating on development of the Ca
About Trans-Hit Biomarkers Inc: Hub, which is aimed at developing a common biorepository
infrastructure that promotes resource sharing and team
Trans-Hit Biomarkers is a privately held company whose science, in order to facilitate multi-institutional, high
mission is to advance innovative biomarkers into more throughput genomic and proteomic studies, Ms. Miranda
valuable and competitive products. Trans-Hit Biomarkers recently authored a new chapter for the NCI Best Practices
is collaborative research organization forging strong focusing on Technical Considerations for Management and
partnerships between human biobanks, preclinical CROs, Operations of Biospecimen Resources. In her role as member
diagnostic companies and technology transfer offices. of the Ca Hub Acquisition of Normal Tissues Working
For further information, please visit: http://www.trans-hit.com/ Group, she collaborated with her ANTWG colleagues on
development of an additional best practice document
focusing on procurement of post mortem tissues. In 2008,
she expanded her consultancy with the incorporation
About visiongain: of Biobusiness Consulting Inc., which serves the global
Visiongainisaspecialistbusinessinformationcompanyfocusedonprovidingcutting
biobanking research communities in government, academia,
edge products and services across the Pharmaceutical/Biotech,Telecommunications, pharmaceuticals, biotech and related industry.
DefenceandFinancesectors,whichincludereports,conferences,onlinedailynewsand
offlinenewsanalysisandbespokeconsultancy.Withacommitmenttoinnovationand Ms. Miranda is also active in numerous professional
excellence,visiongainoffersflexiblesolutionstomeetourclients’businessintelligence societies and committees and has gained recognition as
needs,providingtherightinformationattherighttimetofacilitatethecommercial an international speaker and an expert in Biobanking.
decision-makingprocess.OurpharmaceuticalproductsincludePharmaBusinessDaily, Her current roles include: Councilor on the ISBER Board of
the leading daily email newsletter for the pharmaceutical, biotech and healthcare Directors, membership in the global “think tank” known
industries,andarangeofindependent,high-quality,in-depthreportscoveringfocused
as the “Marble Arch International Working Group on
and topical areas of concern. Our pharmaceutical conferences address the hottest
commercial,regulatoryandtechnicaltopicsandprovideanidealforumfordebateand Biobanking for Biomedical Research”, as well as P3G Society
networkingforpharmaceuticalprofessionalsfromaroundtheworld. (Public Population Project in Genomics), LRIG and the NIH
Biospecimens Special Interest Group.
For further information, please visit: www.visiongain.com

4. Day 1
Biobanking Americas
Wednesday 10th November 2010
09:00 Registration and refreshments 13:40 Science guided biobanking: A prerequisite for the
development of individualized cancer therapies
09:30 Opening address from the chair • Tissues are under tremendous biological stress when surgically separated
from the body and, subsequently, significantly change gene and protein
expression profile and, possibly, also growth regulating factors that might
09:40 NCI’s Cancer Human Biobank (caHUB): Raising the serve as targets or stratification markers for new drugs.
level of excellence for research biorepositories • Several factors have been identified that affect tissue research
data, including:
• The vision for caHUB
- drug treatment and anesthesia of patients before surgical tissue removal
• Planning process for caHUB
- intrasurgical ischemia by ligation of main arteries (warm ischemia)
• caHUB as a national reference repository
- “cold” ischemia, i.e. the time interval between surgical removal and
• Challenges in bioethics and IP fixation of tissue
• White papers available on caHUB operations - location of tumor biopsy within a given tumor
Elaine W. Gunter - processing of tissue and fixation protocols
Founder and President
• Consequently, biobanks for target discovery and drug development have
Specimen Solutions, LLC, National Cancer Institute
to be based on fully controlled, well-documented processes that start
already presurgery and include rapid and standardized tissue preparation
in the surgery unit
10:20 The institutional virtual biobank
Dr. Hartmut Juhl
• Discuss strategies, tools and techniques used for institutional federation CEO, Indivumed and Inostics
and curation of large volumes of disparate data, and present a case-study Adjunct Professor, Georgetown University
for a workflow from repositories to data analysis Adjunct Professor, University of Hamburg
 • Developing a cost-effective workflow to permit computational analysis
will become essential to scientific investigations
14:20 Panel Discussion- Biobanking in 2010
 • High-throughput experimental techniques threaten to dump mountains of
new data onto bioinformatics teams already struggling with the diversity, Panellists will be analysing the recent trends and advancements in sample
complexity and enormity of existing resources collection and processing. Focus will be on the challenges and opportunities
Jeff Milton involved in establishing a biobank. If you want to submit a question, please
Bioinformatics Computational Biology email it to pranita.nangia@visiongain.com
Genentech
15:00 Afternoon Refreshments
11:00 Morning refreshments
11:20 The importance of an Honest Broker function 15:20 Sponsor Spotlight Session
for clinical data associated with biospecimens Take this unique opportunity to be a part of our conference theme, network
• What is an Honest Broker in biobanking? and provide an overview of your product/services to the audience.
For more information please contact ronald.magali@visiongainglobal.com,
• Why is it needed for research?
christopher.clegg@visiongainglobal.com
• What types of research does it support?
• How does it work?
James Eliason 16:00 Biobanking: A golden cusp for tailor made
Director personalised medicines
Stem Cell Commercialisation Center
• Analysing the opportunities, challenges, approaches
• Discussing recent developments
12:00 Biobanking in the Post-genomic Era: • Understanding the ethical, legal guidelines
Methodological Challenges
Dr. John G. Baust 16:40 Closing remarks from the chair
UNESCO Chair Professor, Director
Institute of Biomedical Technology,
State University of New York
16:50 Networking drinks
12:40 Networking lunch
Take your discussions further and build new
relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2010

5. Day 2
Biobanking Americas
Thursday 11th November 2010
09:00 Registration and refreshments 13:40 IT Solutions to support Biobanking
• Biobanks are essential for the transformation of Healthcare, as we move
towards “translational science”, preventive care and personalized medicine.
09:30 Opening address from the chair
• IT Solutions supporting Biobanks must address privacy and security
concerns and should accommodate new data types such as genomic and
imaging data
09:40 Next Generation sequencing at the FDA Center for • To provide value to the medical research community, IT solutions must
be capable of query and analysis and enable the creation of disease
Food Safety and Applied Nutrition. Trace back and
specific repositories
testing of foodborne pathogens
• Examples to be discussed will include Oncology and Neuroscience
• The milestones for this project included: the ability to provide all of the Dr. Michael Hehenberger
data generated from analysis of Salmonella enterica genomes Business Development Executive, Life Sciences
CASE STUDY
• Developed software that will provide full contig assembly of 454 IBM Thomas J. Watson Research Center
genomic data, annotation of those contigs and then generate lists of
genes present in each Salmonella genome based on annotation analysis.
14:20 Recent Legal Developments in Biobanking
• Recent Next gen experience in building a comparative genomics lab • The HITECH Act, the HIPAA Privacy Rule amendments, and their impact
that is directly testing the applications of these methods for foodborne on biobanking
pathogen outbreak detection and analysis
• The affect of the Genetic Information Nondiscrimination Act on informed
Dr. Marc Allard consent for biobanking
Research Microbiologist, Microbiology
FDA-CFSAN-ORS • And more!
Kristen Rosati
Partner
Coppersmith Schermer Brockelman
10:20 Biobanking: changing approaches to target-finding,
drug development and patient treatment
15:00 Afternoon refreshments
Brenda Yanak
West Point IT Site Head and Account Manager, Franchise Biology,
siRNA, Imaging, and GeM 15:20 Biobanking: The Lynchpin for Translational Research
Merck
• So, what’s an imperative for the Biobank?
- The Quality of the specimens, diseased and normal, must be absolutely
11:00 Morning refreshments maintained
- The real value of a Biobank, in either context, is the Meta data (patient
demographics, diagnosis, cohorts, environmental exposure, behavior
11:20 Integrated Healthcare Technologies Solutions for an (smoker/non-smoker), etc.
Aging Society - Whether de-identified or anonymized, or with PHI (Patient Health
• Pharmaceutical company moving towards global healthcare corporation Information), the intrinsic value of biospecimens is in how well and
how thoroughly the specimens are annotated
• Healthcare paradigm shift from traditional inpatient care towards home-
- In the Pharma context, it is also an imperative to validate the
based care
biomarker information via SNP Genotyping, Gene Expression, Flow
• Develop solutions that span from Wellness to Illness care Cytometry or Mass Spectrometry.
• Role of Informatics to enable a consumer healthcare business model - In Medical Research, it essential to track the genealogy of child
samples downstream form the Biobank with a referential link to the
• Vision-Gain from a true integrated and diversified healthcare system parent specimen, as that is where the patient Meta data is stored.
Adel Laoui Dr. Richard J. Maguire
Director, Healthcare Technologies Aging Therapeutic Strategic Unit Director of Business Development – LIMS
Sanofi-aventis Ocimum Biosolutions
16:00 Biobanking : A paradigm shift in drug test and
12:00 Sponsor Spotlight Session development : Mouse to Man
Take this unique opportunity to be a part of our conference theme, network • Assessing tools in improving drug development
and provide an overview of your product/services to the audience. • Overcoming analytical challenges in drug testing
For more information please contact ronald.magali@visiongainglobal.com, • Implementing effective strategies
christopher.clegg@visiongainglobal.com
16:40 Chair’s closing remarks
12:40 Networking lunch
16:50 End of Conference

6. Registration Form
Biobanking Americas
9th - 11th November 2010, Boston, USA
For multiple bookings
Photocopy this form Conf. code VG
Standard Prices Biobanking Americas
Conference and workshop Fee: £1699 VAT: £297.33 Total: £1996.33
Conference only Fee: £1299 VAT: £227.33 Total: £1526.33 9th - 11th November 2010
Workshop only Fee: £599 VAT: £104.83 Total: £703.83
Boston, USA
Promotional Literature Distribution
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £174.83 Total: £1173.83
Details
How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/biobankingamericas
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Main Switchboard Number: Fax: +44(0) 20 7549 9932
Visiongain Ltd
Address: BSG House
226-236 City Road
London
EC1V 2QY
UK
Country: Postcode:
General information
Venue: TBA, Boston, USA
Phone: Fax:
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
Email: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
Signature: Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on
I confirm that I have read and agree to the terms and conditions of booking or after one month before the start of the event. Should you decide to cancel after this date, the
full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable
to transfer places between conferences and executive briefings. However, if you cannot attend the
Methods of payment conference, you may make a substitution/name change at any time, as long as we are informed in
writing by email, fax or post. Name changes and substitutions must be from the same company or
Payment must be made in sterling
organisation and are not transferable between countries.
By Mail: Complete and return your signed registration form together with your cheque payable Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Fax: Complete and fax your signed registration form with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
By Bank Transfer:
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Visiongain Ltd A/C: visiongain Ltd Protection Act 1988. Your personal information contained in this form may be used to update you on
Barclays Bank Sort Code: 20-71-64 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please
48 Regent Street Swift Code: BARC GB22 send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
Please debit my credit card:
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Expiry Date: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Security number (last 3 digits on back of credit card): Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
Signature: with your payment. You will receive your copy of the event CD Rom two weeks after the event.
Yes, please send me a copy of the CD for Price£550 VAT:£96.25 Total:£646.25
Cardholder’s name:
Office use only
News updates
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/biobankingamericas